BioCentury
ARTICLE | Finance

Seeking validation

4Q18 offers glimpse of key data and launch trajectories in large markets

October 6, 2018 12:48 AM UTC

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets.

Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and Biogen Inc. in Alzheimer’s disease will take the spotlight in 4Q18. ...